Subcutaneous Toripalimab Plus Disitamab Vedotin sNDA Is Accepted in China for HER2-Expressing Urothelial Cancer - OncLive
Source: OncLive ·
Subcutaneous Toripalimab Plus Disitamab Vedotin sNDA Is Accepted in China for HER2-Expressing Urothelial Cancer OncLive
BestAIBroker analysis
- Finance-aware sentiment: slightly positive (+0.30 on a -1 to +1 scale).
- Event classification: OTHER.
- Market importance score: 28/100, weighting entity relevance, source credibility, multi-outlet coverage and recency.
- Symbols referenced: FACT.